1. Home
  2. IMNM vs BW Comparison

IMNM vs BW Comparison

Compare IMNM & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$19.35

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Babcock & Wilcox Enterprises Inc.

BW

Babcock & Wilcox Enterprises Inc.

HOLD

Current Price

$14.74

Market Cap

2.8B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
BW
Founded
2006
1867
Country
United States
United States
Employees
N/A
1650
Industry
Medicinal Chemicals and Botanical Products
Building Products
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.8B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
IMNM
BW
Price
$19.35
$14.74
Analyst Decision
Strong Buy
Buy
Analyst Count
10
2
Target Price
$32.80
$8.00
AVG Volume (30 Days)
1.3M
2.8M
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
N/A
EPS
N/A
N/A
Revenue
$6,941,000.00
N/A
Revenue This Year
N/A
$41.58
Revenue Next Year
$1,127.34
$66.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.96
$0.87
52 Week High
$27.65
$22.03

Technical Indicators

Market Signals
Indicator
IMNM
BW
Relative Strength Index (RSI) 46.93 40.57
Support Level $19.28 $13.81
Resistance Level $23.00 $16.24
Average True Range (ATR) 0.84 1.35
MACD 0.21 -0.21
Stochastic Oscillator 49.16 18.05

Price Performance

Historical Comparison
IMNM
BW

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.

Share on Social Networks: